A tunable first-in-class ultrasmall fluorescent core-shell silica nanoparticle bearing site-engineered anti-HER2 single chain variable fragments and topoisomerase inhibitors, eradicates HER2-expressing gastric tumors via a “hit and run” approach without tumor regrowth. This evidence concerns the gene ERBB2 and neoplasm.